We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
U.S. companies taking new biologicals to 11 Pacific Rim nations would get no more than eight years of marketing exclusivity — four less than what they enjoy in the U.S. — under a trade deal agreed to by all 12 countries. Read More
The FDA has banned imports of drugs made by Mumbai, India- based Polydrug Laboratories, citing good manufacturing practice violations at its Ambernath plant. Read More
Active pharmaceutical ingredient maker Pan Drugs was hit with an FDA warning letter and import alert after an inspection revealed significant data integrity and cGMP issues. Read More
In an effort to boost the integrity of the drug supply chain, the FDA has issued a final rule authorizing it to destroy drug imports valued at $2,500 or less that have been refused admission into the country. Read More
An interim report shows that, since 2013, the FDA has conducted nearly 90 meetings with more than 50 drug companies interested in producing biosimilar products — at a cost of $65.9 million. Read More
Amgen and Allergan claim their biosimilar candidate for Roche’s blockbuster Avastin is clinically equivalent in adult patients with advanced non-small cell lung cancer. Read More
Amgen is hoping a Delaware judge will be more agreeable than a California court as it sues Hospira to prevent the biosimilar maker from marketing its challenger to cancer treatment Epogen. Read More
The FDA has approved Impax’s generic versions of Valeant’s Mestinon Timespan tablets and Testred capsules, the first two products approved at the company’s Hayward, Calif., manufacturing plant following resolution of a 2011 warning letter. Read More
The two frontrunners for the Democratic presidential nomination, Hillary Clinton and Sen. Bernie Sanders of Vermont, released prescription drug policy proposals Sept. 22 that would cut prices and end pay-for-delay deals. Read More